In his review Xing (2005) highlighted that among the known common oncogenic genetic alterations occurring in TC, BRAF mutations are the most frequent in PTC, with the prevalence of V600E mutation; BRAFV600E mutation is more frequent in PTC (44% in the studied population) and in PTC-derived ATC tumors (24% of the studied population), compared to other histological subtypes, such as FTC, MTC, or benign thyroid tumors (34). The gene discussed is BRAF; the disease is medullary thyroid gland carcinoma.